A model validation and consensus building environment

SAR and QSAR in Environmental Research

Volumn 17, Issue 3, 2006, Pages 311-321

  Abshear, T ^a   Banik, G M ^a   D'Souza, M L ^a   Nedwed, K ^a   Peng, C ^a  

^a BIO RAD LABORATORIES   (United States)

Author keywords

Consensus; Intrinsic water solubility; Model; Mutagenicity; Plasma protein binding; Validation

Indexed keywords

DRUG PRODUCTS; FORECASTING;

ADME-TOX; CONSENSUS; DRUG DEVELOPMENT; IN-SILICO; INTRINSIC WATER SOLUBILITY; MODEL VALIDATION; MUTAGENICITY; PLASMA PROTEIN BINDING; VALIDATION; WATER SOLUBILITIES;

BIOCHEMISTRY;

EID: 33745815682     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10659360600787551     Document Type: Article

References (22)

1. M.B. Brennan. Chem. Eng. News, 78(23), 63 (2000).
2. T.M. Kennedy. Drug Disc. Today, 2, 436 (1997).
3. H.V.D. Waterbeemd, E. Gifford Nature Rev. Drug Disc., 2, 192 (2003).
4. M.C. Yvonne. Evaluation of commercial ADME prediction programs with Abbott data, paper presented at the 36th Mid-Atlantic Regional Meeting, Princeton, NJ, USA, June (2003).
5. T.R. Stouch. The unfortunate truth behind in silico ADME modeling, paper presented at the Predictive ADME, Improve Lead Selection Through Innovative Thinking, Boston, MA, USA, November (2003).
6. P.F. Stouten. Pitfalls of biopharmaceutical property predictions: stretching data and models too far, paper presented at the Predictive ADME, Improve Lead Selection Through Innovative Thinking, Boston, MA, USA, November (2003).
7. B.E. Mattioni, G.W. Kauffman, P.C. Jurs, L.L. Custer, S.K. Durham, G.M. Pearl. J. Chem. Inf. Comput. Sci., 43, 949 (2003).
8. N. Baurin, J.-C. Mozziconnacci, E. Arnoult, P. Chavatte, C. Marot, L. Morin-Allory. J. Chem. Inf. Comput. Sci., 44, 276 (2004).
9. J.R. Votano, M. Parham, L.H. Hall, L.B. Kier, S. Oloff, A. Tropsha, Q. Xie, W. Tong. Mutagenesis, 19, 365 (2004).
10. PALLAS™, Version 3.0, CompuDrug International Inc., Budapest, Hungary.
11. G.M. Banik. ADME/Tox consensus predictions, paper presented at the Accelerating Drug Discovery to Development via Cutting Edge ADMET, Boston, MA, USA, September (2003).
12. G.M. Banik. Cur. Drug Disc., May, 31 (2004).
13. J.C. Dearden, T.I. Netzava, R. Bibby. J. Pharm. Pharmacol., 54, s-2 (2002).
14. J.R. Votano, M. Parham, L.H. Hall, L.B. Kier. Molec. Diver., 8, 379 (2004).
15. R. Mallela, H. Hitchings, I. Guyon, J. Miller. A comparison of optimized methods on HTS and ADME Datasets, paper presented at Sheffield Cheminformatics Conference, Sheffield, UK, April (2004).
16. R. Mallela, H. Hitchings, I. Guyon, J. Miller. Predictive modeling trends and techniques, paper presented at CHI Predictive ADME/Tox Conference, Boston, MA, USA November (2003).
17. W.M. Meylan, P.H. Howard, R.S. Boethling. Environ. Toxicol. Chem., 15, 100 (1996).
18. K. Subramanian. Strand genomics on learning from the past - building models to predict ADME and toxicity, paper presented at the Evaluating Preclinical Drug Safety Conference, Boston, MA, USA, June (2005).
19. K. Subramanian. Strand genomics on predicting pharmacokinetics of a drug using machine learning, paper presented at the Predictive ADME Conference, Boston, MA, USA, November (2004).
20. J.R. Votano, M. Parham, L.H. Hall, L.B. Kier, S. Oloff, A. Tropsha. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation, paper submitted to: J. Med. Chem. (2005).
21. W.H. Press, S.A. Teukolsky, W.T. Vetterling, B.P. Flannery. Numerical Receipes in C: The Art of Scientific Computing. Chapter 15. Modeling of Data, 2nd Edn, p. 656, Cambridge University Press, New York, USA (1992).
22. Y. Bengio, Y. Grandvalet. Estimators of variance of K-fold cross-validation. Available online at: http://www.iro.umontreal.ca/∼kegl/ CRMWorkshop/slidesGrandvalet.pdf (accessed 15 February 2006).